RELMADA THERAPEUTICS, INC.

RLMD

RELMADA THERAPEUTICS, INC.

RLMD

Insider Sentiment (TTM):

Last Purchase:2025-12-15Last Sale:-Shares Purchased (TTM):1,093,641Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:82,931,386Shares Outstanding:86,596,873Institutional Ownership Pct.:95.77%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Convertible Preferred Stock	-	0	0	-	-	-	0	-	-	-	-	-
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	11	10	3	1	1	1	4	1	2	1	4	7
Short Term Investments	206	224	90	13	19	26	41	53	68	82	92	100
Prepaid Expense Current	1	1	1	1	0	1	1	2	1	1	1	3
Assets Current	219	235	94	15	21	28	46	56	71	84	98	109
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	219	235	94	15	21	28	46	56	71	84	98	109
Liabilities Current
Liabilities And Stockhold…
Accounts Payable Current	2	6	2	1	1	1	4	2	4	5	4	3
Accrued Liabilities Current	5	7	5	4	4	4	6	6	5	7	9	6
Liabilities Current	7	13	6	5	5	5	10	8	10	12	12	8
Program Rights Obligations Noncurrent	5	4	1	0	0	0	0	0	-	-	-	-
Liabilities	13	17	7	5	5	5	10	8	-	12	12	-
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	937	936	785	688	684	681	676	670	662	655	646	636
Retained Earnings Accumulated Deficit	-730	-717	-698	-678	-668	-658	-641	-622	-600	-583	-561	-536
Stockholders Equity	207	219	87	9	16	22	36	48	61	72	85	101
Liabilities And Stockholders Equity	219	235	94	15	21	28	46	56	71	84	98	109
Preferred Class A	-	-	-	0	0	0	0	0	0	0	0	-
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-	-	0.001	0.001	0.001
Preferred Stock Shares Authorized	200	200	200	200	200	200	200	-	-	200	200	4
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	107	105	73	33	33	3	30	30	30	30	30	30
Shares Outstanding	107	105	73	33	33	33	30	30	30	30	30	30

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-20.13%	-15.70%	-28.72%	-	-	-	-	-	-	-	-	-
2025	109.80%	58.29%	48.24%	86.05%	200.66%	248.84%	9.28%	12.63%	-8.51%	16.64%	17.12%	-4.80%
2024	-21.67%	-21.67%	2.61%	-13.58%	4.01%	11.73%	-7.36%	-88.25%	-88.07%	-2.68%	54.70%	134.90%
2023	-	-	-	49.21%	18.11%	17.72%	-16.33%	38.00%	21.00%	-13.41%	-34.26%	-45.07%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	29.52	18.26	14.62	2.86	4.11	5.29	4.45	6.89	7.44	6.82	8.00	12.95
Quick Ratio	29.34	18.15	14.46	2.68	4.02	5.17	4.36	6.69	7.39	6.76	7.90	12.62
Working Capital	211.62M	222.45M	87.55M	9.66M	15.96M	22.43M	35.50M	47.62M	61.44M	72.00M	85.31M	100.68M
Leverage & Debt
Debt to Equity	0.06	0.08	0.09	0.57	0.32	0.23	0.29	0.17	0.16	0.17	0.14	0.08
Interest Coverage TTM	-	-	-	-	-	-	-	-72.78	-35.39	-24.98	-20.13	-23.08
Debt Ratio	0.06	0.07	0.08	0.36	0.24	0.19	0.22	0.15	0.13	0.15	0.13	0.08
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.55	-0.68	-1.45	-1.69	-2.04	-2.49	-2.65	-2.87	-2.88	-3.13	-3.28	-3.71
Free Cash Flow Per Share TTM	-0.41	-0.49	-1.16	-1.20	-1.50	-1.87	-1.72	-1.76	-1.60	-1.60	-1.72	-2.57
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-8.68%	-22.23%	-28.25%	-35.05%	-21.85%	-19.71%	-19.04%	-22.48%	-32.74%	-34.34%	-37.09%	-27.30%
EPS Growth (1Y)	-73.03%	-72.69%	-45.18%	-40.95%	-28.95%	-20.44%	-19.22%	-22.67%	-32.90%	-34.41%	-38.08%	-27.39%
Valuation Metrics
P/E TTM	-12.56	-10.24	-3.32	-1.19	-0.29	-0.11	-0.20	-1.13	-1.04	-1.49	-1.26	-0.81
P/B TTM	3.76	2.76	2.20	7.05	1.25	0.37	0.44	2.05	1.47	1.94	1.46	0.90
Market Cap	777.64M	602.71M	190.69M	66.72M	19.91M	8.21M	15.69M	97.76M	90.52M	140.11M	124.61M	90.30M
Enterprise Value	766.31M	592.94M	191.08M	65.33M	18.56M	7.06M	11.83M	96.28M	88.44M	138.78M	120.52M	83.60M
Calculated Values
Free Cash Flow TTM	-45.99M	-42.79M	-45.79M	-39.99M	-49.92M	-56.79M	-51.76M	-53.21M	-48.18M	-48.19M	-51.66M	-77.29M
Net Debt	-11.33M	-9.78M	391.00K	-1.38M	-1.35M	-1.15M	-3.86M	-1.48M	-2.09M	-1.34M	-4.09M	-6.70M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-15Purchase

Owner: Traversa, Sergio

Title: Chief Executive Officer

Shares: 27,500

Price/Share: $4.12

Value: $113,300.00

Shares Owned: 1,300,000

Relationship: Director,Officer

Ownership: Direct

2025-12-15Purchase

Owner: Shenouda, Maged

Title: Chief Financial Officer

Shares: 11,665

Price/Share: $4.12

Value: $48,059.80

Shares Owned: 800,000

Relationship: Officer

Ownership: Direct

2025-11-05Purchase

Owner: Kelly, Paul Edward

Title: Chief Operating Officer

Shares: 90,000

Price/Share: $2.20

Value: $198,000.00

Shares Owned: 502,295

Relationship: Director,Officer

Ownership: Direct

2025-11-05Purchase

Owner: Traversa, Sergio

Title: Chief Executive Officer

Shares: 272,500

Price/Share: $2.20

Value: $599,500.00

Shares Owned: 1,272,500

Relationship: Director,Officer

Ownership: Direct

2025-11-05Purchase

Owner: Ence, Chuck

Title: CAO and COO

Shares: 136,000

Price/Share: $2.20

Value: $299,200.00

Shares Owned: 403,931

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-15	Traversa, Sergio	Director,Officer	Chief Executive Officer	Direct	Purchase	27,500	4.12	$113,300.00	1,300,000	4
2025-12-15	Shenouda, Maged	Officer	Chief Financial Officer	Direct	Purchase	11,665	4.12	$48,059.80	800,000	4
2025-11-05	Kelly, Paul Edward	Director,Officer	Chief Operating Officer	Direct	Purchase	90,000	2.20	$198,000.00	502,295	4
2025-11-05	Traversa, Sergio	Director,Officer	Chief Executive Officer	Direct	Purchase	272,500	2.20	$599,500.00	1,272,500	4
2025-11-05	Ence, Chuck	Officer	CAO and COO	Direct	Purchase	136,000	2.20	$299,200.00	403,931	4
2025-11-05	Shenouda, Maged	Officer	Chief Financial Officer	Direct	Purchase	500,000	2.20	$1,100,000.00	788,335	4
2025-08-28	Traversa, Sergio	Director,Officer	Chief Executive Officer	Direct	Purchase	55,976	0.74	$41,422.24	1,000,000	4
2025-05-20	Traversa, Sergio	Director,Officer	Chief Executive Officer	Direct	Purchase	147,686	0.56	$82,704.16	734,024	4
2025-05-20	Shenouda, Maged	Officer	Chief Financial Officer	Direct	Purchase	60,000	0.52	$31,200.00	288,335	4
2025-05-16	Kelly, Paul Edward	Director,Officer	Chief Operating Officer	Direct	Purchase	200,000	0.43	$86,000.00	412,295	4
2025-05-16	Ence, Chuck	Officer	CA and CO	Direct	Purchase	228,961	0.45	$103,032.45	267,931	4
2024-09-11	Shenouda, Maged	Officer	Chief Financial Officer	Direct	Purchase	24,120	2.95	$71,154.00	88,335	4
2024-09-11	Traversa, Sergio	Director,Officer	Chief Executive Officer	Direct	Purchase	51,407	2.99	$153,706.93	384,024	4
2024-09-09	Kelly, Paul Edward	Director	-	Direct	Purchase	25,000	2.59	$64,750.00	212,295	4
2024-09-09	Casamento, Charles J	Director	-	Direct	Purchase	13,000	2.56	$33,280.00	13,000	4
2024-01-31	Ence, Chuck	Officer	CA and CO	Direct	Purchase	13,670	4.05	$55,363.50	38,970	4
2024-01-31	Traversa, Sergio	Director,Officer	Chief Executive Officer	Direct	Purchase	27,460	4.00	$109,840.00	244,024	4
2024-01-31	Shenouda, Maged	Officer	Chief Financial Officer	Direct	Purchase	6,875	4.06	$27,912.50	34,903	4
2023-05-23	O'Gorman, Cedric	Officer	Chief Medical Officer	Direct	Purchase	10,000	3.18	$31,800.00	10,121	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

95.77%

Inst. Shares: 82,931,386

Shares Outstanding: 86,596,873

2025-12-31

127.59%

Inst. Shares: 50,371,733

Shares Outstanding: 39,479,694

2025-09-30

21.40%

Inst. Shares: 7,104,590

Shares Outstanding: 33,191,622

2025-06-30

14.07%

Inst. Shares: 4,669,716

Shares Outstanding: 33,191,622

2025-03-31

16.19%

Inst. Shares: 4,923,096

Shares Outstanding: 30,408,890

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	82,931,386	86,596,873	95.77%
2025-12-31	50,371,733	39,479,694	127.59%
2025-09-30	7,104,590	33,191,622	21.40%
2025-06-30	4,669,716	33,191,622	14.07%
2025-03-31	4,923,096	30,408,890	16.19%
2024-12-31	6,874,015	30,163,751	22.79%
2024-09-30	10,856,638	30,174,202	35.98%
2024-06-30	12,069,137	30,174,202	40.00%
2024-03-31	12,776,628	30,132,170	42.40%
2023-12-31	11,894,718	30,099,203	39.52%
2023-09-30	13,195,661	30,099,203	43.84%
2023-06-30	14,097,000	30,099,203	46.84%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

RELMADA THERAPEUTICS, INC. (RLMD) — SEC Financial Statements & Analysis

RELMADA THERAPEUTICS, INC. (RLMD) is a pharmaceutical preparations company, incorporated in NV. RELMADA THERAPEUTICS, INC. trades on Nasdaq as: RLMD. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), RELMADA THERAPEUTICS, INC. reported a Debt-to-Equity ratio of 0.06x, a Price-to-Book (P/B) ratio of 3.76x (TTM), at a market cap of $777.64M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.06x
P/B TTM: 3.76x
Market Cap: $777.64M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is RELMADA THERAPEUTICS, INC. in?

RELMADA THERAPEUTICS, INC. (RLMD) operates in the Pharmaceutical Preparations industry.

What is RLMD's market cap?

RELMADA THERAPEUTICS, INC. (RLMD) has a market capitalization of $777.64M as of 2026-06-30.

What exchange does RLMD trade on?

RELMADA THERAPEUTICS, INC. (RLMD) trades on the Nasdaq.

Where is RELMADA THERAPEUTICS, INC. incorporated?

RELMADA THERAPEUTICS, INC. is incorporated in NV.